Medicines Optimisation Centricity
Is it creating health inequalities? Or could working much more collaboratively, with a full range of partners, improve the use of medicines in the NHS, saving money and improving patient care.
These were two topics that have been explored through a series of workshops, initiated and funded by Aspire pharma, and facilitated and run by HSJ (previously Wilmington Healthcare). The workshops brought together key NHS and Pharmacy stakeholders, to discuss both individual topics.
Reimagining Medicines Optimisation: A Call to Action for Reducing Health Inequalities
In July 2024, HSJ Advisory, in their second partnership with Aspire Pharma Ltd, brought together NHS and pharmacy stakeholders to discuss a critical issue in healthcare: is medicines optimisation contributing to health inequalities? The discussions held during this roundtable highlighted several systemic challenges which were further explored at the HSJ Medicines Forum in October 2024.
These discussions exposed an urgent need for reform in how medicines optimisation is approached. It is clear that without strategic intervention, inequalities in patient care will only widen, leading to a detrimental impact on public health outcomes. The following article details some of the key takeaways from the events, as well as a proposed path forward for the NHS and industry leaders.
It’s time to optimise medicines optimisation
In March 2023, HSJ Advisory (previously Wilmington Healthcare), in partnership with Aspire Pharma Ltd, worked with various NHS experts to discuss the importance of ensuring that the right patient gets the right medicine, at the right dose and time for the right indication, and whether this process is effective and truly patient centric.
The discussions explored and indicated a need for all stakeholders across the NHS and services beyond, including patients themselves, to work more collaboratively to gain optimised medicines optimisation.
MOC1010347C2_OCT2024